Pharmaceutical Care Management Association (PCMA)’s Post

Happy World Pharmacists Day! Une merveilleuse Journée Mondiale des Pharmaciens et Pharmaciennes à tous et à toutes! Did you know: -There are 42,500 licensed pharmacists in Canada? -On top of providing pharmaceutical care in community settings, around 15% work in hospitals and 15% in various settings such as governments, associations, academia and industry? -That pharmacists are considered the most accessible health-care professionals -That pharmacists are providing care to patients for 750 million prescriptions per year? https://lnkd.in/gJYABWfF -Pharmacists around the world are meeting global health needs with sustainable development goals? https://lnkd.in/gTrPyUjf

FDA's CDER Quality Standards Program posted two additional consensus standards to support pharmaceutical quality. These updates are part of CDER's Program for the Recognition of Voluntary Consensus Standards Related to Pharmaceutical Quality aimed at advancing regulatory consistency and encouraging adoption of recognized quality standards across the pharmaceutical industry. Visit the page to explore the latest additions and see how they align with CDER’s mission of ensuring safe, effective, and high-quality medications are available to all Americans ➡️ https://lnkd.in/eTrGd75F

If you are interested in assessing Active Pharmaceutical Ingredients for reduction of bioburden or sterilization, please enjoy reading the full article! #ActivePharmaceuticalIngredients #Sterilization

Increasingly stringent product sterility requirements and guidance are being included in global regulatory documents issued by regulatory bodies such as the European Medicines Agency (EMA) and the Food and Drug Administration (FDA). Ophthalmic products 👁, where the drug product requires application directly into the eye are one of the leading therapeutic areas subject to heightened regulatory scrutiny. This Industry Insight summaries study findings of the key benefits of terminal sterilization and/or aseptic processing when applied to Active Pharmaceutical Products (APIs). Read more today ➡️https://lnkd.in/eiSdj5UZ

✨ In case you missed it ✨ The European Medicines Agency recently published new guidance for industry and notified bodies to clarify the regulatory requirements for devices used in combination with pharmaceutical products. 🔗 in the comments #medtechnews #regulatoryaffairs #medicaldevices

What services are Pharmacists offering for free and how much time do these services consume❓ Today I presented our preliminary results at #PSA24 Pharmaceutical Society of Australia

Pharmaceutical distribution needs to be agile, efficient and compliant. Alan Kennedy introduces the GDP-UCI pharmaceutical good distribution practice (GDP) model to an attentive audience at the Global Pharma Supply Chain and Logistics Conference in Shanghai on March 28th and 29th 2024.

Join us this March 21st, 4pm-5:30pm, for a crucial webinar on Navigating the Ethical Landscape: A guide to the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) live on Zoom! 📚 Gain insights into ethical pharmaceutical marketing practices and explore the impact of UCPMP regulations. Don't miss out on this informative session! #UCPMP #EthicalMarketing #PharmaIndustry #WebinarAlert #ZoomEvent" https://lnkd.in/gvAB7CAF Dr Swadeep Srivastava Daleep Manhas

Discover the EMA's newly revised guidelines for therapeutic equivalence and pharmaceutical quality of inhalation and nasal products, and share your feedback by October 2024. #medicalaffairs #medicinesdevelopment #GMDPacademy #EMA

Update in the British Pharmaceutical Industry On 23 September 2024, the Association of the British Pharmaceutical Industry (ABPI) and the Prescription Medicines Code of Practice Authority (PMCPA) unveiled the updated “orange” 2024 Code of Practice and came into effect on October 1st. This new Code introduces significant changes to: - PMCPA Constitution and Procedure - Provision of Prescribing Information - Mandatory Requirements The updated Code aims to elevate the high standards expected of pharmaceutical companies and expedite the resolution of complaints. Key highlights include a new abridged complaints process and enhanced authority for the Appeal Board. The updated 2024 Code introduces a new requirement at Clause 5.2, mandating that all company personnel maintain a high standard of ethical conduct and comply with all relevant Code requirements. To support this, companies must now have clear policies and provide appropriate training to communicate corporate standards and expectations. However, it is important to note that Clause 5 clarifies that a breach can be found even where an employee is “acting contrary to the instructions which they have been given”. https://www.pmcpa.org.uk/ #PharmaceuticalIndustry #ABPI #PMCPA #CodeOfPractice #Healthcare #Compliance #PatientSafety